Abstract: How does a small molecule blocking a few receptors change a patients' passionately held paranoid belief that the FBI is out to get him? To address this central puzzle of antipsychotic action, we review a framework linking dopamine neurochemistry to psychosis, and then link this framework to the mechanism of action of antipsychotics. Normal dopamine transmission has a role in predicting novel rewards and in marking and responding to motivationally salient stimuli. Abnormal dopamine transmission alters these processes and results in an aberrant sense of novelty and inappropriate assignment of salience leading to the experience of psychosis. Antipsychotics improve psychosis by diminishing this abnormal transmission by blocking the dopamine D2/3 receptor (not D1 or D4), and although several brain regions may be involved, it is suggested that the ventral striatal regions (analog of the nucleus accumbens in animals) may have a particularly critical role. Contrary to popular belief, the antipsychotic effect is not delayed in its onset, but starts within the first few days. There is more improvement in the first 2 weeks, than in any subsequent 2-week period thereafter. However, a simple organic molecule cannot target the complex phenomenology of the individual psychotic experience. Antipsychotics diminish dopamine transmission and thereby dampen the salience of the preoccupying symptoms. Therefore, in the initial stage of an antipsychotic response, the patients experience a detachment from symptoms, a relegation of the delusions and hallucinations to the back of their minds, rather than a complete erasure of the symptoms. Only with time, and only in some, via the mediation of new learning and plasticity, is there a complete resolution of symptoms. The implications of these findings for clinical care, animal models, future target discovery and drug development are discussed.
INTRODUCTION
The introduction of chlorpromazine, in the 1950s, opened the era of modern antipsychotics, and since then dozens of antipsychotics have been developed and tested. In the 1960s, the idea that these antipsychotics were acting on the dopamine system took hold, a finding confirmed in the 1970s, and in the 1980s and 1990s the role of dopamine in psychosis was more firmly confirmed using neuroimaging studies.
Thus, whereas the role of dopamine in the biology of psychosis and a role for blocking dopamine receptors in the mechanism of antipsychotics is widely accepted-it still remains unclear how one links these neurobiological and pharmacological or "brain level" findings with the essentially phenomenological "mind-level" nature of psychosis and its resolution. In this article, we review a heuristically useful framework, derived from the role of dopamine in "salience" and psychosis, that allows one to bring together these different levels of analysis.
We begin with a brief review of the current accounts about the role of dopamine in emotion and behavior, with a particular emphasis on notions of reward, reward prediction, and salience. We use these concepts to then develop a framework that can potentially explain the phenomenology of psychosis and the phenomenological aspects of antipsychotic response. The framework then leads to a number of natural questions: Which dopamine receptors are relevant for antipsychotic response? How quickly after the onset of the biological action of antipsychotics does psychosis start improving? What do the patients' experience? How does this change the kind of animal models we seek?
The article is not a comprehensive review. Rather it represents a selective and limited review of data as they relate to the above questions with a particular bias toward the role of the dopamine system. The article is limited in that it focuses mainly on one neurotransmitter system (dopamine), whereas it is quite clear that other systems (e.g., glutamate, serotonin) are involved and interact; furthermore, it focuses on one major symptom type (psychosis), although it is well recognized that a number of other symptom types (cognitive, negative symptoms, affective) also carry major weight in the illness of schizophrenia. However, the effort here is to provide a coherent account within this focused area, rather than catalog a broad range of findings. As such, this article borrows from a number of previous articles and reviews published by our group and others, and where appropriate the reader is referred to these original articles for details and references.
THE SALIENCE FRAMEWORK FOR PSYCHOSIS AND ANTIPSYCHOTICS?
There is near universal agreement for a central role of dopamine in "reward" and "reinforcement"-although precisely what these terms mean and what dopamine contributes to their realization continues to be a matter of debate. These competing ideas are discussed in much greater detail in earlier articles 1,2 -and are excerpted here from those texts.
One of the earliest scientifically supported ideas about the role of dopamine suggested that dopamine mediates hedonic pleasure. 3 However, subsequent studies showed that dopamine is involved not only in appetitive events but also in aversive ones; 4 and the release of dopamine often precedes the hedonic experience. 5, 6 To accommodate these and other findings, several complementary ideas have developed over time. At one level of analysis, the firing of the midbrain dopamine neurons is linked to "reward prediction." 7, 8 In this role, the dopamine system alters its firing when the animal encounters novel rewards in the environment or when well learnt associations are violated-i.e., when an unexpected new reward is found or an expected reward is omitted. 7 This event-linked, self-terminating action occurs at subsecond time scale and has been demonstrated by measuring the burst firing of dopamine neurons and the release of phasic dopamine in the limbic regions. 7, 9 However, increases in dopamine of a much longer duration (minutes to hours) have been observed by microdialysis and have been linked to responses to rewarding stimuli. This longer time scale role of dopamine is thought to mediate the "motivational salience" of environmental stimuli and their associations. 10, 11 Motivational salience refers to the process whereby reward-associated stimuli come to be attention grabbing to the animal and become the focus of goal-directed behavior. This release of dopamine is thought to not only direct and accentuate the animals responses in the present situation, but also facilitates the "stamping in" of new associations and reward learning that guides future behavior. 12 Thus, the dopamine system is involved in detecting new rewards in the environment, enhancing the animal's learning about the rewards and their associations, and driving goal-directed behavior. These reward-related functions, when combined with dopamine's well-established role in the motor system, allow for a seamless conversion of motivation to action. 13 What then is the relationship of dopamine to schizophrenia? It is beyond the scope of this chapter to review this issue in great detail-the reader is referred to authoritative and comprehensive reviews of this matter. 14 -18 The themes that emerge are: 1) there is an aberrantly hyperdopaminergic state in schizophrenia; 2) this state is most closely tied to the expression of "positive" or "psychotic" symptoms; and 3) the hyperdopaminergia is perhaps the results of a dysfunction in genes and transmitters that indirectly regulate dopamine. How does one link the role of dopamine to the expression of psychosis?
Under normal circumstances, the context-driven activity of the dopamine system mediates the experience of novelty, the acquisition of appropriate motivational salience, and learning of appropriate associations. 10, 11, 19, 20 However, in the psychotic state, the abnormal context-independent firing and release to dopamine leads to the creation of aberrant novelty and salience.
1 Figure 1 portrays this framework. In this framework, the cycle of events that begins with a series of genetic and environmental predispositions (FIG. 1) 17,21 that result in a dysregulated dopamine system that fires and releases dopamine independent of cue and context (FIG. 1) . Kapur 1 postulated that, during the prodrome to psychosis, this context-independent or context-inappropriate firing of dopamine neurons and dopamine release produces in patients an aberrant sense of novelty and salience (FIG. 1) 2 -a state well captures in these patients' accounts of the prodromal period: "I developed a greater awareness of . . . my senses were sharpened. I became fascinated by the little insignificant things around me;" or "sights and sounds possessed a keenness that he had never experience before;" or "noticed things I had never noticed before."
1 Patients continue to accumulate these experiences of altered novelty and salience without a clear explanation for them. There is a gradually increasing sense of perplexity, confusion, and alterations in mood and behavior until it crystallizes into a delusion (FIG. 1) . 22, 23 Delusions in this framework are a "top-down" cognitive explanation that the individual imposes upon these aberrant novelty/salience experiences in an effort to make sense of them (FIG. 1) . Because the patient constructs the delusions, he or she is imbued with the psychodynamic themes and cultural context of the individual. Hallucinations in this framework are thought to arise from a conceptually similar processthey reflect the abnormal salience of the internal representations of percepts, language, and memories. 1 Sooner or later, these delusions or hallucinations impact the patient's behavior-and this is typically when patients are brought to care and antipsychotics are administered (FIG. 1) .
Antipsychotics, by blocking dopamine receptors, block the neurochemical milieu that was inciting aberrant salience, and instead provide a milieu wherein new aberrant salience is less likely to form and established aberrant salience are more likely to extinguish (FIG. 1) . 24 -26 Thus, the disappearance of delusions and hallucinations is a dynamic process wherein antipsychotics block dopamine and thereby lessen the salience of the concerns, the patient works through their symptoms toward a psychological resolution (FIG.  1) .
26,27 However, antipsychotics attenuate salience across the board-and this may explain why patients find antipsychotics "dysphoric," and as a result noncompliance with these medications continues to be high (FIG. 1) . 1, 28 Although antipsychotics block the expression of a disordered dopamine system, they do not reverse the underlying etiology or the disorder in the dopamine system. Thus, when antipsychotics are stopped (or sometimes even in their presence under periods of extreme stress or illicit drug use), the dopaminergic dysregulation remanifests itself (FIG. 1) . The same ideas, schemes, and percepts that were previously part of the patient's symptoms become reinvested with salience once again and direct thought and behavior.
The ideas presented above are a heuristic framework rather than a single testable hypothesis. They serve to bring together ideas from different stages of the illness (prodromal, psychotic, residual) at different levels of analysis (neurochemical, psychological, pharmacological). The framework suggests a number of questions-we focus on a few selected ones.
WHICH DOPAMINE RECEPTORS ARE CRITICAL FOR ANTIPSYCHOTIC RESPONSE?
In the discussions above, we speak broadly of a "dopamine" system, although it is clear now that the dopamine system constitutes a number of midbrain neuronal collections that give rise to distinct projections to target regions in the striatum (nigrostriatal projections), limbic regions (mesolimbic projections), prefrontal cortex (mesocortical projections), and more recently a distinct pathway to the thalamus. 29 Whereas all dopamine receptors link to G proteins, they are further classified into two families: the D1-like receptor subfamily (including D1 and D5), which activates adenylate cyclase via their coupling to the G␣s subunits; and the D2-like receptor subfamily (including D2, D3, and D4 receptors), which decreases adenylate cyclase levels via G␣i/o subunits and effects other proteins and ion channels via the release of G␣␤␥ subunits from receptor coupling. 30, 31 If the dopamine system is critical to antipsychotic action: Which dopamine projections? Which receptor subtypes?
The idea that dopamine receptors were involved in antipsychotic action can be traced back to the early observation that antipsychotics increased the turnover of monoamines, 32 more specifically dopamine. 33 This anticipated the discovery of a dopamine receptor, but it was not until the mid-70s that a precise receptor was identified. 34 -36 Although that receptor was originally christened as the "neuroleptic receptor"-with the differentiation of the D1 and D2 subfamilies, 37 it became clear that the neuroleptic receptor was the D2 receptor. A central role for dopamine D2 receptor occupancy in antipsychotic action is now well established and has been documented in several positron emission tomography (PET) and single-photon emission tomography neuroimaging studies.
-41
The imaging studies have provided a more precise estimate of the relationship between the level of occupancy and outcome. Because there are a large number of papers, we can only summarize the conclusions here, and readers are referred to more detailed analyses elsewhere.
41-44 All typical antipsychotics block dopamine D2 receptors, and it seems that blockade of 60 -70% receptors is required to reach a threshold of antipsychotic activity, beyond which there is little evidence of enhanced antipsychotic efficacy. Doses of antipsychotics that lead to occupancies higher than 80%, cause a much higher incidence of extrapyramidal side effects. The situation with atypical antipsychotics such as risperidone, olanzapine, and ziprasidone is generally similar, although some subtle differences (5-10%) in thresholds for response and/or extrapyramidal side effects (EPS) between the typicals and these atypicals, cannot be ruled out because definitive head-to-head PET studies testing the thresholds have not been performed. Thus, this 65-80%"window" seems to cover the majority of the prescribed antipsychotics. However, two major deviations emerge.
Clozapine and quetiapine-two atypical antipsychotics with a lower incidence of EPS-are clinically effective at levels of D2 occupancy in the 40% range. [45] [46] [47] Aripiprazole, on the other hand, seems to require greater than 85% D2 occupancy to be effective at clinical doses, and at the same time does not induce EPS despite almost complete saturation of dopamine D2 receptors. 48 It has been proposed that even in these agents, blockade of dopamine D2 receptors is critical to their action-however, the lower affinity and faster dissociation of clozapine/quetiapine 49 and the partial agonism of aripiprazole 50 allow them to achieve this blockade with apparently different levels of striatal D2 occupancy.
What about the other dopamine receptors? Given the prominent role for dopamine D1/5 receptor subfamily in reward and reward-related learning, it is quite plausible that dopamine D1 receptor antagonism contributes toward an antipsychotic effect. However, several small studies have failed to find evidence to that effect-and there is a suggestion that D1 blockade by itself may even exacerbate the psychotic symptoms.
51-55 Although D1 antagonism seems an unlikely mechanism for an antipsychotic effect, its role as an adjuvant to D2 blockade 56 and the potential role of D1 agonism are under active consideration.
57
Data linking the effects of antipsychotics to dopamine D2 receptors is largely derived from in vitro and in vivo studies that use radioligands that do not specifically distinguish the D2 from the D3 and D4 subtype. This finding, coupled with the fact that the D3 subtype is preferentially distributed in the mesolimbic regions, has generated a lot of interest in the possibility that the therapeutic effects of antipsychotics may be D3 mediated, whereas the motor side effects may be the result of the nigrostriatal D2 blockade. 58, 59 Although the concept is attractive, there is no clinical test of this proposition as specific ligands for the dopamine D3 receptors are not widely available. At the same time, a number of indirect pieces of evidence argue against a role for the D3 receptors as the main locus of antipsychotic action 60, 61 ; some small-scale trials with initial agents have been negative 62, 63 ; and others suggest a role for D3 in the amelioration of negative and cognitive symptoms, rather than positive symptoms.
59 Dopamine D4 -another member of the D2 subfamily-was a subject of intense interest with regards to antipsychotic action because initial data suggested that the D4 receptors were elevated in schizo-phrenia and were related to efficacy in refractory patients. 64 -66 However, as more specific and selective agents have become available and have been tested in large-scale trials, agents with selective for 67, 68 and those with high affinity for the D4 receptor 69 have been found to be devoid of antipsychotic efficacy.
Given the central importance of the D2 receptors, the question arises as to which target regions are most critical for the antipsychotic effect. Dopamine D2 receptors are observed in the nigrostriatal, mesolimbic, mesocortical, the newly defined thalamic, and the tubero-infudibular dopamine systems. 29 In vitro studies fail to find structural or functional differences in the D2 receptors expressed across these regions. 70 Whereas the dopamine D2 receptors express themselves in two alternative splice-variants (D2-short and D2-long), the differential anatomical distribution of these variants and its relevance for antipsychotic effect is not clear. [71] [72] [73] One can exclude the tubero-infunidbular system on theoretical grounds (changes in prolactin are unlikely to be mediating antipsychotic effect) and on empirical grounds (prolactin effects and antipsychotic effects are uncorrelated) 74, 75 -it is harder to choose between the other regions. The general strategies for addressing this question have involved measuring the regional impact of antipsychotics on D2 receptors in terms of receptor occupancy 76 and functional markers, 77 and relating these changes to the system level effects of antipsychotics in humans and animals.
Because the dopamine D2 receptors are similar across target regions and antipsychotics show similar penetration into the different brain regions (cf. pituitary system) 78 as dose is increased, an effect of D2 blockade can be discerned in all the regions bearing D2 receptors. Thus, any claims to regional specificity are only relative in nature. When the effects of antipsychotics on the induction of immediate-early gene-product FOS 79, 80 and the depolarization of afferent dopamine neurons [81] [82] [83] are measured, one observes a preferential effect in the mesolimbic dopaminergic regions (nucleus accumbens) as opposed to the nigrostriatal dopaminergic regions (dorsolateral caude-putamen). 77 This focus on the mesolimbic dopamine system is theoretically plausible because the accumbens and the mesolimbic system in general are implicated in processing reward and motivational drives, 12,84 -86 processes that are critical to the generation of psychosis per the "salience" hypothesis. However, most of the preclinical data implicating the mesolimbic dopamine system are derived from studies in rodents wherein the mesocortical and the mesothalamic systems are underdeveloped in comparison to humans.
Of the human studies, most focus on "striatal" dopamine D2 receptor blockade, mainly because the first generation of imaging ligands gave good signals only from these regions. However, there is increasing interest in examining the effects of antipsychotics in the extrastriatal regions (mainly the thalamus, frontal, and temporal cortex). Some reports suggest that atypical antipsychotics (clozapine, olanzapine, sertindole, risperidone, and amisulpride) show a preferential blockade of the cortical dopamine D2 receptors compared with striatal dopamine D2 receptors. 87, 88 These reports have been questioned on methodological grounds, 89 and there are an equal number of reports that fail to find such striatalextrastriatal differences. 90 -93 However, the question of greater interest is not the quantitative level of occupancy, but its clinical significance. A recent study by Agid et al. 94 randomized patients to different levels of striatal and extrastriatal D2 occupancy as measured using 11C-raclopride and 11C-FLB457, respectively, and observed that only the striatal, not the extrastriatal, D2 occupancy predicted response.
HOW SOON AFTER DOPAMINE BLOCKADE DO ANTIPSYCHOTIC EFFECTS TAKE PLACE?
Answer: "The onset of antipsychotic response is delayed." This idea of a "delayed onset" of antipsychotic action gained favor in the 1970s and is now firmly embedded in standard psychiatric textbooks. [95] [96] [97] [98] According to this hypothesis, there is a delay of 2-3 weeks from the initiation of medication to the onset of specific therapeutic benefits, even though dopamine receptor blockade is well established in the first few days. The "depolarization block" hypothesis has been proposed as an explanation for this delay. This hypothesis suggests that the effect of repeated antipsychotic administration on dopaminergic neurons in the brain is inactivation of firing and this inactivation takes place only after 3 weeks (21 days) of continuous treatment. It has been suggested that this 3-week period may explain the delay in onset of both the therapeutic effect and the neurological side effects of these drugs on schizophrenic patients. During the last two decades, more than 1050 articles have cited the papers describing the "depolarization block" hypothesis, 99 -109 attesting to the wide scientific acceptance of this idea.
Brain imaging has provided a direct window to the speed with which dopamine blockade is achieved in humans. Nordstrom et al. 110 observed the speed-of-onset of dopamine blockade in response to receiving haloperidol, and Tauscher et al. 93 have reported the effects of the atypical antipsychotic medications, risperidone and olanzapine. These studies unequivocally demonstrate a robust blockade of the dopamine system within hours of drug administration. Given that the blockade of the dopamine system is rather immediate, the idea of a "delayed onset" provides a particular stumbling block for the theory of a direct relationship between dopamine, dopamine blockade, psychosis, and antipsychotics.
The issue regarding the start of action of antipsychotics has been obscured by confusion between the "onset" (i.e., departure from baseline) and reaching a certain arbitrary threshold (say 30% or 40% improvement). Undoubtedly, reaching "full therapeutic effect" takes a number of weeks or months. 111 This, by itself, does not imply a delay in the "onset" of action. In most areas of therapeutics (psychiatric or otherwise), medications take time to deliver their full benefits-only rarely does that imply a "delayed onset" of action. The "onset of action" of a drug usually takes place at an earlier point than reaching the full therapeutic effect of that drug. The earliest reports of chlorpromazine treatment in the 1950s 112, 113 describe responses within days. Moreover, some of these 1950s studies report an early response that is over and above changes in sedation or level of agitation. 114, 115 Over the subsequent years, several others have raised the issue of an early onset of antipsychotic response (e.g., Stern et al., 116, 117 McDermott et al., 118 Garver et al., 119, 120 and others), although the issue has never been systematically studied in large-scale and controlled trials.
A number of recent findings demonstrate that the onset of improvement is rather immediate after dopamine blockade. In a recent meta-analysis, 121 42 published studies were identified which provide data on 7450 patients during the first 4 weeks of antipsychotic treatment. The percentage reductions in total scores of the Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS) were: 13.8% during the first week, 8.1% during the second week, 4.2% during the third week, and 4.7% during the fourth week. This pattern of "early" onset improvement was present even after the estimated effect of placebo was removed and when results were restricted to the psychotic subscales of the BPRS and the PANSS. This meta-analysis rejected the commonly held hypothesis that antipsychotic response is delayed. Rather, the findings suggest that the antipsychotic response starts in the first week of treatment and accumulates over time.
Whereas the above study describes the antipsychotic response within the first week, a recent report 122 tested whether there is an onset of an antipsychotic effect within the first 24 h. In a multicenter, double-blind, placebo-controlled study, 311 patients with a diagnosis of schizophrenia spectrum disorder were randomly assigned to receive 10 mg i.m. of olanzapine, 7.5 mg i.m. of haloperidol, or i.m. placebo. The olanzapine and haloperidol groups showed greater resolution of overall symptoms than the placebo group. An independent change in the psychotic symptoms was evident for both medications within the first 24 h of treatment. Most recently, Leucht et al. 123 confirmed the "early onset of antipsychotic action hypothesis" in data from seven randomized trials including 1708 amisulpride treated patients with schizophrenia, and showed that the reduction of overall symptoms and positive psychotic symptoms until the second week of treatment was larger than the additional symptom reduction until the fourth week. Furthermore, they found that the majority of the improvement that the subjects will experience in the first year is already observed within the first few weeks of treatment. Although these data lay to rest the traditional "delayed onset" hypothesis, it does not change the reality that, even after months of treatment, most patients with schizophrenia psychosis are not in full remission, but continue to harbor some elements of their psychotic ideas. So, what exactly about psychosis changes with antipsychotics?
WHAT IS THE PATIENT'S EXPERIENCE WITH ANTIPSYCHOTICS?
Although a considerable amount of scientific effort has been expended at describing how symptoms or clusters of symptoms change, 124 -127 almost all of this work entails the clinicians' assessment of how the drugs are impacting the patient. While some studies have focused on drug side-affects and their acceptability as well as studying the impact of drugs on the quality of life, 128 -135 little attention has been paid to how patients' experience the "antipsychotic" effect. In a recent study, we investigated a large group of chronically treated patients to ask what their medications did for their psychotic experiences using a structured questionnaire. 136 A principal components analysis of the patients' responses revealed two major factors that explained 71% of the variance. The first factor included items such as "help me deal," "help me stop thinking" and "not bother"-a factor termed detachment. The second factor included the statements "change my mind" and "take away"-termed eradication. Chronically treated patients report that antipsychotics seem to "detach" them from their symptoms rather than "eradicate" them. When we gave the same questionnaire to a set of patients who had never experienced antipsychotics (neuroleptic naive) their response showed that they expected that the medications will both "detach" and "eradicate" symptoms. However, after the first 6 weeks of antipsychotic treatment, these neuroleptic-naive patients revised their opinion and gave a much higher rating to the ability of the antipsychotics to "detach" them from their symptoms, rather than "eradicate" them.
To follow up on these findings, we investigated in greater detail how the experience of psychosis changes after the beginning of antipsychotic medications. Using a newly developed scale, the Dimensions of Psychosis Experience Scale (DOPE-S), which identifies four different dimensions: cognitive and emotional preoccupation (CEP) with psychotic symptoms (delusions and/or hallucinations); behavioral impact (BI) of the symptoms; conviction (CO) in the symptoms; and ability to adopt an external perspective (EP) on their appropriateness-we followed drug-free patients that were started on antipsychotic medications for the first 6 weeks of antipsychotic treatment. 137 The data showed that BI showed the greatest improvement (32%) at 2 weeks; CEP responded next (19%); the improvement in CO was limited (6%); and EP showed no improvement, despite the conventional degree of improvement in PANSS positive subscale (17%). After 6 weeks of antipsychotic treatment, the relative severity of the BI, CEP, and CO had become quite similar to the pattern observed in the chronically treated patients that was recorded in another separate group or chronically treated patients (n ϭ 91) in whom the BI dimension had the lowest score.
These results are consistent with the view that the antipsychotics do not primarily take away the symptoms, they first reduce the impact of the symptoms by reducing the behavioral impact and the cognitive and emotional preoccupation with the psychotic experience. In light of recent evidence suggesting an earlier onset of therapeutic antipsychotic effects, 121, 138 our findings are of interest because they identify the particular aspects of psychosis (i.e., BI) on which antipsychotics appear to exert their earliest effects.
These results are also consistent with earlier intuitive observations made by Laborit and Huguenard, who reported in 1951 that patients given these drugs showed "désintéressement," a disinterest, in their surroundings. 139, 140 Whereas some patients do actually achieve complete resolution of their delusions and hallucinations with antipsychotic treatment, for many patients a detachment from their symptoms and a reduction in the BI and CEP is as good as resolution as antipsychotics can provide. This detachment may be necessary to allow patients to refrain from responding behaviorally, cognitively, and emotionally to aberrantly salient ideas or percepts (FIG. 1) .
IMPLICATIONS OF THESE DEVELOPMENTS FOR ANIMAL MODELS
Animal models play an essential role in understanding the neurobiological and behavioral mechanisms of antipsychotics as well as for aiding drug discovery. Most of currently used models have high predictive validity for antipsychotic effect (e.g., conditioned avoidance response, catalepsy test, paw test, etc.), [141] [142] [143] some possess construct validity (e.g., amphetamine-induced prepulse inhibition deficit and latent inhibition deficit, phencyclidine-induced social interaction deficit, etc.) 144 -146 or neurobiological construct validity (e.g., neonatal hippocampal lesions, genetic models, etc.). 147 However, none of these preparations provides a good model of the early onset, progressive enhancing effect of repeated antipsychotic treatment. Animal models that are based on the single acute antipsychotic treatment regimen (e.g., the usual use of latent inhibition 148 and prepulse inhibition 149 ) by definition, cannot model the progressive long-term antipsychotic effect or relapse. Other models (such as "depolarization block" 102 antipsychotic-induced Fos or FosB expressions;
150 chronic prepulse inhibition model 151 ) have used chronic treatment regimens but have often examined behavioral or physiological changes after the certain period of treatment has elapsed (e.g., ϳ21 days after the first drug administration), under the assumption of a "delayed onset" of antipsychotic action. Thus, it is unclear if these models capture the time course of antipsychotic response shown in humans.
The conditioned avoidance response (CAR) model has been used to study antipsychotic-like compounds for more than 50 years and has shown quite robust predictive and construct validity. 152, 153 In a typical experiment, a rat is placed in a two-compartment shuttle box and presented with a neutral conditioned stimulus (CS, e.g., white noise), followed by a mildly aversive unconditioned stimulus (US, e.g., footshock). The rat may escape the shock US by moving from one compartment to the other. Notably, after several CS-US pairings, the rat typically moves during the CS, thereby avoiding the US. Once acquired, avoidance responding is remarkably resistant to extinction. Animals will respond for hundreds of trials without receiving a single shock. 156 Under certain circumstances, they may keep making avoidance responses even after they are prevented to respond to the CS. 154, 155 This persistent nature in the face of contradictory evidence renders avoidance responding a delusionlike phenomenon (a fixed false belief). In this sense, the CAR model may even possess some face validity of schizophrenic delusions and may explain why the anti-"psychotic" property of a drug in this model is indexed by a selective disruption on this behavior.
Previous animal research has shown that all antipsychotics (typical and atypical, including the newer partial agonists such as aripiprazole) 156 selectively disrupt avoidance responding at doses which do not alter unconditioned escape response. 153 Other classes of psychotropic drugs (e.g., anxiolytics, barbiturates, MAOIs) do not possess this property. 141, 153 The potency of antipsychotics to inhibit avoidance responding is found to be positively correlated with their clinical potency against psychotic symptoms (predictive validity). 141 Recent reports show that the level of dopamine D2 occupancy (ϳ70%) that causes a disruption in avoidance responding in animals is in the same range as that found in schizophrenic patients that show effective antipsychotic response 157 -thus indicating a common underlying neuro-biological mechanism between CAR disruption in animals and antipsychotic response in humans (neurobiological construct validity). Finally, studies examining behavioral mechanisms responsible for CAR effects of antipsychotics suggest that the drugs may act by dampening the animals' response to the motivationally salient conditioned stimulus, 11, 158, 159 consistent with the suggestion regarding their mode of action in patients (FIG. 1) .
However, most implementations of CAR have focused on single-exposure studies with the main objective of identifying a "signal" of whether the drug is likely to be an antipsychotic or not. As in other models, little attention has been paid to the issue of onset, progressive increase, relapse, etc. More recently, we have observed that the disruptive effect of typical as well as atypical antipsychotics, which starts on day 1 of testing is progressively enhanced with each subsequent drug testing (an across-session decline) 160 and the decline curve obtained with the CAR model was qualitatively similar to the symptom improvement observed in patients-consistent with the framework outlined in Figure 1 . Interestingly, once the treatments were stopped, rats gradually reinstated their avoidance responding analogous to the gradual, but in most cases an inevitable, relapse observed in patients when the antipsychotics are stopped (FIG.  1) . 161 Given the selective nature of this review, we do not wish to claim primacy for the CAR model above other competing models. However, what is encouraging is that we have reached a stage where we can relate animal models to frameworks of human disease not only at a predictive, but, also at a neurobiological, behavioral and therapeutic level.
ADVANCES, YES. BUT, STILL LOOKING FOR A BREAKTHROUGH
Although one can take comfort that the science of antipsychotics is progressing steadily, it is still humbling to realize that 50 years after the introduction of the very first antipsychotic, we are still playing with the same main mechanism of action (D2), that the efficacy of the newer drugs is not notably better than those of the older ones, and the gold standard for efficacy (clozapine) is still a drug discovered by serendipity over four decades ago. 162 Thus, whereas the field can claim many advances-the site of action of the current antipsychotics is known, can be visualized by PET imaging, can be used to predict dosing guidelines, time-course of onset is clearer, the impact on patients is more comprehensively understood-a genuine breakthrough has eluded us. What might such a breakthrough look like? In the view of the authors two domains look hopeful. A "clinical" breakthrough (likely driven by pharmacogenetics 163 or imaging 43 ) would be the ability to predict, prospectively, which of the nearly 100 available antipsychotics will be optimal for a given patient. 164, 165 A "mechanism" breakthrough would entail bypassing the dopamine D2 receptor as the only target of efficacy-this may occur either through targeting other transmitter systems that regulate dopamine systems (e.g., glutamate, 17 neurokinins 166 etc.); or via acting directly on the intracellular messenger and trafficking systems that D2 receptors invoke to implement their actions (e.g., the newly discovered Akt-GSK pathway, 167 the proteins that regulate the trafficking of D2 receptors, 168, 169 or mechanisms that alter receptor-receptor cross-talk 170, 171 etc.). Thus, while on the one hand, the future of this field, buoyed by advances in imaging, genetics, and molecular biology looks particularly ripe for a breakthrough in the next decade, our history of over half a century has a more humbling lesson to teach. 
